Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today it
Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today it will host a virtual Key Opinion Leader (KOL) event today at 9:00am ET to discuss its NKT cell therapy programs.
Athenex had previously announced best responses from five patients of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR) from the ANCHOR Phase 1 study of KUR-502 (allogeneic CD19 CAR-NKT cells) in relapsed /refractory lymphoma and leukemia. At the ASH Annual Meeting yesterday, the Company provided updated results from the study, which included a conversion of one patient (NHL-4) treated with dose level (DL) 2, from a PR to a CR. Safety profile of treatment with the allogeneic CAR-NKT cells remains favorable and further enrollment is ongoing.
Register for the KOL webinar on the Investor Relations portion of the website.
The webinar will feature presentations by KOLs Leonid Metelitsa, M.D., and Carlos Ramos, M.D., both from Baylor College of Medicine, and Sattva Neelapu, M.D., from MD Anderson Cancer Center. Dr. Metelitsa will provide an overview of Athenex's CAR-NKT cell-based approaches. Dr. Ramos will discuss the interim data from the ongoing ANCHOR study evaluating KUR-502 in relapsed or refractory lymphoma and leukemia. Dr. Neelapu will discuss the current treatment landscape and unmet medical needs in lymphoma and leukemia.
Presentations from Kurt Gunter, M.D., Chief Medical Officer for Cell Therapy at Athenex, and Daniel Lang, M.D., President of Athenex Cell Therapy, will follow to discuss clinical milestones and company objectives.
A question-and-answer session will follow the formal presentations.
About the Phase I Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Patients with Relapsed or Refractory B-Cell Malignancies (ANCHOR)
The phase I study is an open-label, dose-escalation study. NKT cells were isolated from the leukapheresis product of one HLA-unmatched healthy individual, transduced with the CAR, expanded ex vivo for 14 days (99.8% NKT purity), and cryopreserved. Patients received 107 (DL 1) or 3×107 (DL 2) CAR-NKT cells per square meter of body surface area following lymphodepleting conditioning with cyclophosphamide/fludarabine. Adverse events were evaluated per NCI criteria. When accessible, patients underwent core biopsies of an involved site at 2-5 weeks post-infusion. Response to therapy was assessed at 4 weeks per Lugano Criteria (for NHL) or NCCN guidelines (for ALL).
For further information about the study, visit ClinicalTrials.gov, identifier: NCT03774654.